Our cost analysis confirms this potential by demonstrating a savings of $49.87 per ASCUS case, $156.81 per LSIL case, and $162.16 per ASC-H case. There are obviously several assumptions that must ...
Consecutively accessioned cases diagnosed with atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells-cannot ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback